GlassScriptPhysician profile
Douglas T Shepherd
NPI 1659482289
$1,283.65
in general payments reported to CMS, 2019-2025
24 companies · $337 in 2025
The $337 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $237 · 2021: $101 · 2022: $90.60 · 2023: $121 · 2024: $125 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $582.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $203.75 | 2019-2025 | Relistor, Trulance |
| Averitas Pharma INC. | $138.99 | 2024-2025 | Qutenza |
| Biodelivery Sciences International, INC. | $100.13 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $90.41 | 2019-2021 | |
| Abbvie INC. | $88.62 | 2023-2025 | Ubrelvy, Botox |
| Merz Pharmaceuticals, LLC | $79.74 | 2025 | Xeomin |
| Pfizer INC. | $78.67 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $68.41 | 2019-2021 | |
| Azurity Pharmaceuticals, INC. | $56.04 | 2023-2025 | Horizant, Horizant |
| Nevro Corp. | $46.82 | 2022 | |
| Boston Scientific Corporation | $41.84 | 2019-2025 | General - Pain Management |
| Scilex Pharmaceuticals INC. | $41.07 | 2019 | |
| Abbott Laboratories | $38.08 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $37.52 | 2019 | |
| Medtronic USA, INC. | $28.67 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $25.85 | 2020-2021 | |
| Medtronic, INC. | $19.82 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.65 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $15.83 | 2023 | Seglentis |
| International Rehabilitative Sciences, INC | $14.71 | 2023 | Rs 4i Plus Sequential Stimulator |
| Eisai INC. | $14.50 | 2020 | |
| Shionogi INC | $12.94 | 2019 | |
| Allergan, INC. | $12.21 | 2020 | |
| Amgen INC. | $11.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Shepherd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.